invertebrates (18, 24) and these transgenic flies, compared to their control (mCherry) 148 counterparts, showed enhanced survival after infection with S. aureus due to reduced 149 biofilm formation and lower bacterial counts (18). The mCherry-expressing transgenic 150 flies serve as a control for flies expressing an exogenous protein under the control of the 151 same promoter (24). To investigate synergy of antibiotics within this model system, 152 gentamicin was microinjected one day after bacterial infection of flies. Synergy was 153 observed in iafgp-transgenic flies treated with gentamicin, with significantly enhanced 154 survival compared with untreated iafgp-transgenic flies ( Figure 1A ). In contrast, mCherry 155 control flies, untreated, or treated with gentamicin, displayed similar survival curves 156
( Figure 1A ). These survival data were corroborated with significantly lower bacterial 157 counts measured at 3, 4, and 5 days after gentamicin treatment in iafgp-transgenic flies 158 Fig 1C) . These results 160 demonstrate that antibiotics can successfully boost the ability of iafgp-transgenic flies to 161 fend off biofilm-associated bacterial infections. 162
163
We previously demonstrated protection of iafgp-transgenic mice against MRSA 164 (18). Since IAFGP enhanced daptomycin activity in vitro (see Table 1 Having explored the synergistic properties of IAFGP with antibiotics using 180 transgenic flies and mice (see Figure 1 and 2), we next sought to investigate the role of 181 P1, an IAFGP derivative (18, 19) Figure 3A) . To ensure the peptides themselves did not have any 187 deleterious effects on fly survival, uninfected mCherry-expressing flies were assessed for 188 survival upon P1 or sP1 injection ( Supplementary Fig 2) . In the absence of any bacterial 189 infection, there was no statistically significant difference among fly survival with either 190 peptide treatment group ( Supplementary Fig 2) . Treatment with 2.5 μg/mL of gentamicin, 191 one-day post S. aureus infection, significantly bolstered survival rates of the P1 group 192 compared to the antibiotic free cohort (dotted line, Figure 3A ); no significant difference 193 was found between the sP1 groups that did or did not receive gentamicin. Synergy 194 between P1 and gentamicin was corroborated with bacterial viability counts showing a 195 significant decrease at days 3 and 5 ( Figure 3B ). These data demonstrate that P1 compared to second-generation catheters coated with chlorhexidine and silver 208 sulfadiazine (31, 32). We therefore tested whether P1 could influence the ability of S. 209 aureus to attach to these antibiotic-impregnated catheters. Having found synergy between 210 P1 and rifampicin or minocycline in a plate assay (Supplementary Table 2 Gentamicin is not commonly used to treat S. aureus, except in some cases of 294 combinatorial therapy associated with the treatment of endocarditis (37); Ciprofloxacin 295 and other fluoroquinolones are often used for broad-spectrum coverage; Daptomycin, is a 296 potent lipopetide based antibitoic prescribed against MRSA infections. IAFGP and P1 297 increased the activity and efficacy for each of these antibiotics against S. aureus and its 298 drug-resistant counterpart. These studies highlight the diversity of IAFGP's synergistic 299 capacity --enhancement in the activity of antibiotics such as gentamicin or ciprofloxacin, 300 which are not usually used specifically for S. aureus, or the improved effect of highly 301 specific antibiotics such as daptomycin. against Streptococcus pneumonia and S. aureus, the most common Gram-positive 310 pathogens in community-acquired pneumonia (40, 41) . Despite these mitigating factors, 311 daptomycin, in our own murine nasal infection models, yielded a 20 to 50% survival 312 advantage with half the optimal dosage-25 mg/kg body weight vs. 50 mg/kg body weight 313 (42), among iafgp-transgenic mice, demonstrating synergy in more complex biological 314 systems, at a lower dose versus traditional therapeutics strategies. We also observed 315 synergy in a surgical catheter implant model, highlighting a potential application of P1, 316 as prophylactic coating for catheters and other indwelling devices such as heart valves, 317 pacemakers or prosthetic implants. S. aureus infection in flies is associated with biofilm 318 formation (18). Morbidity, during these bacterial infections, can be attributed to systemic 319 bacterial dissemination from the biofilm architecture. Our observations using P1 alone, 320 and in concert with antibiotics within control flies, demonstrates the prophylactic utility 321 of P1 as a systemic anti-virulence agent that can target bacterial biofilms. Moreover, the 322 absence of in vitro cytotoxicity adds further weight towards either protein or peptide as a 323 potent prophylactic (Supplementary Fig. 3 ). In battling infections, disabling microbial 324 virulence attributes in vivo can shift the advantage to the host and render bacteria 325 increasingly susceptible to host defenses and antibiotics. 
405
Purified IAFGP-GST was prepared as previously described (18). Briefly, iafgp, 406 without its signal sequence, was PCR amplified from pGEMTiafgp (50) and cloned into 407 pGEX-6p-3 (GE Healthcare, Piscataway, NJ). Protein expression was induced with 1 mM 408 IPTG and bacteria were lysed using a French pressure cell press at 20,000 pounds per 409 square inch. Following centrifugation, IAFGP-GST was affinity purified using GST 410 Sepharose (GE Healthcare, Piscataway, NJ) eluted and stored in aliquots at −80°C. 411
Precision protease treatment or dialysis resulted in IAFGP degradation. Therefore, the 412 GST-tagged protein in elution buffer was used for experiments. Recombinant GST was 413 purified from pGEX-6p-3 following the same protocol and used as a control. The iafgp-expressing and their control mCherry-expressing flies were generated 446 as described (24) . D. melanogaster was maintained using standard procedures. The fly 447 colony was maintained at 21-23°C. Following infection, flies were incubated at 29°C to 448 increase upstream activation sequence (UAS)-mediated transgene expression. Five to 9 449 day old females were used for experiments. Twenty to 30 flies per vial were infected by 450 microinjection and survival was monitored (51). Microinjection was performed into the 451 thorax below the wing using a Nanojet microinjector (Drummond Scientific, PA). 452
Bacteria in stationary growth phase were diluted in PBS to OD 600 =0.1 and 9.2 nL was 453 injected, corresponding to an infectious dose of approximately 1000 CFU/fly. Antibiotics 454 (gentamicin and daptomycin at 2.5 μg/mL) were administered 24 hours post-infection in 455 a similar fashion. Individual flies were homogenized in 500 μL PBS using a bullet 456 blender and steel beads (Nextadvance, NY). Serial dilutions were plated on brain-heart-457 infusion agar plates and incubated at 37°C overnight. Microinjection of mCherry-458 expressing wildtype flies with either peptide (P1 or sP1) was done one day prior to 459 infection at a final dose of 1.0 mg/mL (42 μM). The concentration administered was ten 460 times higher than that previously used to inhibit biofilms (18) to prevent repeat injections. Murine catheter implant surgery was performed as described previously (52) . 477
Mice were anesthetized using isoflurane inhalation and a dorsal area was shaved. 478 Cell suspensions were spotted on 2% agarose pads containing PBS and 540 phase/epifluorescent microscopy images were acquired using an Eclipse Ti-U microscope 541 (Nikon, Japan) outfitted with an Orca-ER camera (Hamamatsu, Japan). Image processing 542 and quantitative analysis were performed using MATLAB (MathWorks, Natick, MA). 543
Each cell included in the analysis were detected using a modified version of MATLAB 544 scripts described elsewhere (54). Integrated, total signal intensities were normalized on a 545 per cell basis, according to area, and the average signal intensity for each population was 546 with 10% fetal bovine serum (FBS) at 37°C and 5% CO 2 unless otherwise noted. The 556 lactate dehydrogenase assay was performed using the Lactate Dehydrogenase Activity 557 Assay Kit as described by the manufacturer (Sigma, St. Louis, MO). Briefly, 1,200 to 558 2,000 actively growing cells in 200 μL were seeded into individual wells of a 96-well 559 plate and were incubated for 24 h. DMEM or F12 supplemented with 2% FBS was 560 diluted 1:1 with PBS containing 0.4 mg/mL, 0.2 mg/mL, 0.1 mg/mL, or 0 mg/mL of 561 IAFGP, GST, P1 or sP1. 100 μL of treated medium was added to wells of the 96-well 562 plate and allowed to incubate for 24 h. The supernatant was used in the colorimetric 563 assay, and the 96-well plate was read at A 450 using a microtiter ELISA plate reader 564 (BioTek, Winooski VT). Each treatment was performed in duplicate and two biological 565 replicates were performed for each cell line. Two biological replicates containing two 566 technical replicates were performed for each cell line and media condition. 567 568
Statistical analysis. 569 570
All experiments were repeated independently at least 3 times, if not noted 571 otherwise. One representative experiment or pooled data are shown. Statistical 572 differences between experimental and control groups were analyzed using using Prism 573 6.0 software (GraphPad Software Inc., CA). Significance was determined using Two-574 
